Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pegfilgrastim.

Monique P Curran1, Karen L Goa

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|May 16, 2002
PubMed
Summary
This summary is machine-generated.

Single-dose pegfilgrastim effectively reduces febrile neutropenia incidence and duration in cancer patients receiving myelosuppressive chemotherapy. This pegylated G-CSF offers a convenient alternative to daily filgrastim injections.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum to: Maclobemide.

Drugs·2017
Same author

Erratum to: Moclobemide.

Drugs·2017
Same author

Erratum to: Cyclosporin: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Immunoregulatory Disorders.

Drugs·2017
Same author

Decitabine: a review of its use in older patients with acute myeloid leukaemia.

Drugs & aging·2013
Same author

Tadalafil: in the treatment of signs and symptoms of benign prostatic hyperplasia with or without erectile dysfunction.

Drugs & aging·2012
Same author

Transdermal granisetron: a guide to its use in preventing nausea and vomiting induced by chemotherapy.

CNS drugs·2012
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology
  • Hematology

Background:

  • Pegfilgrastim is a pegylated form of filgrastim, a recombinant human granulocyte colony-stimulating factor.
  • It is designed for single-dose administration per chemotherapy cycle to mitigate infection risk in non-myeloid cancer patients.
  • Pegfilgrastim modifies the pharmacokinetics of filgrastim, extending its half-life and reducing serum clearance.

Purpose of the Study:

  • To evaluate the efficacy and safety of single-dose pegfilgrastim compared to daily filgrastim in patients with non-myeloid cancer undergoing myelosuppressive chemotherapy.
  • To assess the impact of pegfilgrastim on the incidence of febrile neutropenia and the duration of severe neutropenia.

Main Methods:

  • Phase II and III clinical trials were conducted in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease.

Related Experiment Videos

  • Patients received either a single dose of pegfilgrastim or daily injections of filgrastim during chemotherapy cycles.
  • Key endpoints included the duration of grade 4 neutropenia, time to absolute neutrophil recovery, and the incidence of febrile neutropenia.

    • Main Results:

    • In cycle 1, the duration of grade 4 neutropenia and time to neutrophil recovery were similar between pegfilgrastim and filgrastim groups.
    • In subsequent cycles (2-4), single-dose pegfilgrastim significantly reduced the mean duration of grade 4 neutropenia compared to daily filgrastim.
    • The incidence of febrile neutropenia was significantly lower in the pegfilgrastim group in a large phase III trial for breast cancer patients.
    • Adverse events, including skeletal pain, were comparable between the two treatment groups.

    Conclusions:

    • Single-dose pegfilgrastim is an effective and safe alternative to daily filgrastim for reducing the incidence and duration of neutropenia in cancer patients.
    • Pegfilgrastim's pharmacokinetic profile supports its extended dosing schedule, offering potential benefits in patient convenience and treatment adherence.